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44 Lentiviral vector-mediated expression of RNA interference for
ENaC in cell models of airway epithelium suitable for functional
evaluation of ENaC activity
E. Copreni, S. Castellani, L. Palmieri, M. Conese. H. S. Raffaele, Milan, Italy
In cystic ﬁbrosis (CF) the epithelial sodium channel (ENaC) hyperactivitity plays a
role in the pathogenesis of chronic lung disease, caused by depletion of the perciliary
liquid layer and impaired mucus clearance. We have demonstrated that a HIV-based
lentiviral (LV) vector containing a RNA interference cassette for the alpha subunit of
human ENaC (alphaA2shRNA) and NGFR (Nerve Growth Factor Receptor) could
efﬁciently knockdown the expression of ENaC mRNA in H441 human respiratory
cells. Formation of domes (ﬂuid-ﬁlled hemicystis which are marker of ENaC
localization to the cell membrane) and functional assay of ENaC activity were
established. H441 cells were seeded onto 96 well plates and two days later 50 nM
dexamethasone (dex) was added to the medium which was changed every day.
Domes appeared three days after dex addition and one week after dome formation
membrane potential assay (Molecular Devices) was performed. Membrane potential
assay showed that ENaC channel is active in our cell model due to the fact that
addition of amiloride decreased cell-associated ﬂuorescence in a dose dependent
manner. Domes were transduced with the LV vector alphaA2shRNA-LV and NGFR
gene expression determined by ﬂow cytometry, resulting in only 0.6% of transduced
cells. When cells were infected the day before dome appearance, LV efﬁciency
rised to 92% of NGFR expressing cells. Our study shows that alphaA2shRNA-LV
efﬁciently transduce H441 cells organized in domes, a functional model for the
study of ENaC activity. We acknowledge L. Naldini for providing the LV vectors.
Supported by: the Italian Cystic Fibrosis Research Foundation, by the Associazione
Lombarda Fibrosi Cistica and EU grant n. 005213.
45* Preclinical evidence that sildenaﬁl corrects cystic ﬁbrosis defects
B. Lubamba1, H. Lecourt1, T. Coste1, J. Lebacq1, P. Lebecque1, H. De Jonge2,
P. Wallemacq1, T. Leal1. 1Universite´ Catholique de Louvain, Brussels, Belgium;
2Erasmus University Medical Center, Rotterdam, Netherlands
Sildenaﬁl has been implicated in the activation of CFTR protein by correcting
location to the apical membrane of DF508 mutation (Dormer et al, 2005). This
effect was observed in vitro and in the presence of doses roughly 300 larger than
those commonly used for the treatment of erectile dysfunction. The aim of our study
was to evaluate in vivo therapeutic efﬁcacy of clinical doses of sildenaﬁl, a clinically
approved type V phosphodiesterase inhibitor, for correcting CF defects. We mea-
sured transepithelial potential difference across the nasal mucosa as a readout for
sodium and chloride conductance. Both CF animal models showed ion transport
abnormalities similar to those observed in CF patients, i.e. hyperpolarization in
baseline conditions; increased response to amiloride, which blocks ENaC; reduced
hyperpolarization after perfusion with Cl-free solution containing amiloride and
with forskolin, a cAMP agonist. The effect of a single intraperitoneal injection
of sildenaﬁl (0.7mg/kg) was investigated in DF508/DF508, cftr knockout and
normal homozygous mice. In DF508/DF508, but not in cftr knockout mice, chloride
conductance, evaluated by perfusing the nasal mucosa with a Cl-free solution in
the presence of amiloride and with forskolin, was corrected 1 h after sildenaﬁl
administration. The forskolin response was increased after sildenaﬁl in both normal
and DF508 mutant animals. No effect on sodium conductance was detected in any
group of animals. Our results provide preclinical evidence that sildenaﬁl, applied in
vivo, in pharmacological doses, corrects chloride transport defects of DF508-CFTR
protein.
Supported by grants from the French CF Association (VLM) and by an Educational
grant from Pﬁzer Belgium.
46* Deposition and pharmacokinetic studies with inhaled P2Y2
agonists – evidence of high lung delivery and minimal systemic
exposure
D. Kellerman1, S. Warren2, A. Rossi1, G. Taylor2, L. Smiley1. 1Inspire
Pharmaceuticals, Inc., Durham, NC, USA; 2Cardiff Scintigraphics Ltd., Cardiff,
United Kingdom
We report here three studies with the inhaled P2Y2 agonists diquafosol and
denufosol (in Phase 3 at present) to characterize lung disposition and absorption
following administration via a PARI LC Star nebulizer/compressor system to healthy
volunteers. In the ﬁrst two studies (n = 12 per study – non-smokers and smokers),
40mg (in 4mL) of diquafosol, radiolabelled with Technetium-99m DTPA, was
administered over 12−15 minutes, and lung deposition was quantiﬁed using gamma
scintigraphy. Total mean lung dose in the non-smokers and smokers was 7.12mg and
6.95mg, respectively, indicating that approximately 17−18% of the loaded dose was
deposited in the airways. In a third study, the systemic pharmacokinetics of 200mg
(in 4mL) of denufosol given via inhalation were assessed in 12 healthy volunteers in
an IV crossover study. Most plasma levels during and 8 hours following nebulization
were below the limit of quantitation (1 ng/mL), and relative bioavailability was
calculated to be less than 3%. The half-life from the IV (0.1mg/kg) portion of the
study was less than 1 minute. Thus, despite high deposition of P2Y2 agonists into
the airways, there appeared to be little or no systemic exposure, probably related
to limited absorption from the airways and/or very rapid metabolism in blood or
lung. CF patients are currently receiving 60mg denufosol administered via a PARI
LC Star nebulizer three-times daily in an ongoing Phase 3 study, TIGER-1.
47 Reactive airway disease and cystic ﬁbrosis: a retrospective
analysis of the safety and tolerability with denufosol inhalation
solution
A. Rossi, V. Brandi, J. Engels, J. Gorden, A. Schaberg, L. Smiley. Inspire
Pharmaceuticals, Inc., Durham, NC, USA
The contribution of reactive airway disease (RAD) including asthma to the course
of cystic ﬁbrosis (CF) lung disease and to CF patients’ tolerability to medications
is poorly understood. Clinical outcomes of CF patients with and without RAD were
examined retrospectively in two 28-day Phase 2 safety and tolerability studies with
denufosol. These studies included CF patients 8 years of age with a predicted
FEV1 75% (Study 08–103) and 60–90% (Study 08–104). For this analysis
patients with RAD were retrospectively identiﬁed by a history of RAD, asthma
and/or wheezing. Of 161 CF patients randomized and dosed, seventy patients were
classiﬁed as having RAD (placebo n = 22; denufosol n = 48) and 91 patients not
having RAD (placebo n = 23; denufosol n = 68). Patients with RAD were generally
more likely to be male, DF508 homozygous, and use concomitant medications
such as corticosteroids, inhaled tobramycin, leukotriene receptor antagonists, and
other anti-asthmatics. A higher percentage of RAD patients used b-agonists (83%)
compared to non-RAD patients (63%) and a higher percentage had Pseudomonas
aeruginosa colonization at baseline compared with non-RAD patients (63% vs.
38%, respectively). The incidence of and withdrawal due to treatment-emergent
adverse events was similar between both groups. No serious adverse events occurred
in the RAD group and 4 occurred in the non-RAD group. In conclusion, the clinical
course and tolerability to denufosol of RAD CF patients was not different from
that of non-RAD CF patients in two studies with denufosol. The inclusion of RAD
patients in the ongoing Phase 3 study, TIGER-1, with denufosol that includes CF
patients 5 years old is appropriate.
